Regulation of cancer cell migration and bone metastasis by RANKL.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Bone metastases are a frequent complication of many cancers that result in severe disease burden and pain. Since the late nineteenth century, it has been thought that the microenvironment of the local host tissue actively participates in the propensity of certain cancers to metastasize to specific organs, and that bone provides an especially fertile 'soil'. In the case of breast cancers, the local chemokine milieu is now emerging as an explanation for why these tumours preferentially metastasize to certain organs. However, as the inhibition of chemokine receptors in vivo only partially blocks metastatic behaviour, other factors must exist that regulate the preferential metastasis of breast cancer cells. Here we show that the cytokine RANKL (receptor activator of NF-kappaB ligand) triggers migration of human epithelial cancer cells and melanoma cells that express the receptor RANK. RANK is expressed on cancer cell lines and breast cancer cells in patients. In a mouse model of melanoma metastasis, in vivo neutralization of RANKL by osteoprotegerin results in complete protection from paralysis and a marked reduction in tumour burden in bones but not in other organs. Our data show that local differentiation factors such as RANKL have an important role in cell migration and the tissue-specific metastatic behaviour of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDA-231 cells and other human breast cancer cells have been shown to express RANK (101, 336)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [336]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
Dissemination and growth of cancer cells in metastatic sites
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc865 · Cited by 3,911
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Self-citationMetastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00103-3 · Cited by 756
Self-citation
Cited by
Items 401–500 of 864
Oh, J., Kim, J., Kim, H.-S., Oh, J. C., Cheon, Y.-H., Park, J., Yoon, K., Lee, M. S., & Youn, B. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608786 · Cited by 24
A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor
Ko, Y. J., Sohn, H. M., Jang, Y., Park, M., Kim, B., Kim, B., Park, J., Hyun, H., Jeong, B., Hong, C., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.368 · Cited by 23
Osteoimmunology — Bidirectional dialogue and inevitable union of the fields of bone and immunity —
Takayanagi, H. (2020) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.96.013 · Cited by 23
Ji, L., Zhang, W., Zhong, X., Zhao, T., Sun, X., Zhu, S., Yu, T., Luo, J., Xu, Y., Yang, D., et al. (2022) · Frontiers in Oncology · doi:10.2139/ssrn.4117344 · Cited by 23
Timotheadou, E. T., Kalogeras, K. T., Koliou, G.-A., Wirtz, R. M., Zagouri, F., Koutras, A. K., Veltrup, E., Christodoulou, C., Pentheroudakis, G. E., Tsiftsoglou, A. P., et al. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.05.006 · Cited by 23
“RANKL also stimulates the migration of RANK-expressing tumor cells, primary breast epithelial cells, and osteoclasts [5].”
BackgroundValverde, A., Serafín, V., Montero‐Calle, A., González-Cortés, A., Barderas, R., Yáñez‐Sedeño, P., Campuzano, S., & Pingarrón, J. M. (2019) · ChemElectroChem · doi:10.1002/celc.201902025 · Cited by 23
A missense mutation sheds light on a novel structure–function relationship of RANKL
Qiu, H., Qin, A., Cheng, T., Chim, S. M., Smithers, L., Chen, K., Song, D., Liu, Q., Zhao, J., Wang, C., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30045 · Cited by 23
“RANKL has been implicated in the migration and metastatic behavior of cancer cells (Jones et al., 2006), and its bidirectional signal has recently been found to reversely regulate osteoblastogenesis (Zhang et al., 2017), suggesting that RANKL may be a therapeutic target for the treatment of…”
BackgroundTranslational cell biology of highly malignant osteosarcoma
Roessner, A., Lohmann, C. H., & Jechorek, D. (2021) · Pathology International · doi:10.1111/pin.13080 · Cited by 23
Peters, S., & Meylan, E. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835d720b · Cited by 23
Labovsky, V., Vallone, V. B. F., Martinez, L. M., Otaegui, J., & Chasseing, N. A. (2012) · Cancer Cell International · doi:10.1186/1475-2867-12-29 · Cited by 23
“Additionally, RANK is expressed in many different epithelial tissues and epithelial tumor cells, and in vitro stimulation of human BC cell lines (MDAMB-231, MCF-7 and Hs578T) with RANKL results in concentration-dependent cell migration, which is blocked by recombinant OPG [7].”
BackgroundInfluentialBandyopadhyay, A. M., Wang, L., Chin, S. H., & Sun, L. (2007) · Neoplasia · doi:10.1593/neo.06784 · Cited by 22
“pressing RANK [29].”
The Physiology and Pathophysiology of the Osteoclast
Peruzzi, B., & Teti, A. M. (2011) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-011-9086-6 · Cited by 22
“In addition, cancer cells are as well sensitive to RANKL [239], which induces the expression of EMMPRIN, a cell surface glycoprotein that increases the expression by tumor cells of MMP9 and VEGF, two factors that stimulate tumor cell invasion, angiogenesis and osteoclast formation [240].”
BackgroundVidula, N., Yau, C. S. F., Li, J., Esserman, L. J., & Rugo, H. S. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4318-1 · Cited by 22
“In melanoma cells, RANKL promoted the migration of RANK-expressing cancer cells to bone [20].”
BackgroundBone biology and the role of the RANK ligand pathway.
Murthy, R. K., Morrow, P. K. H., & Theriault, R. L. (2009) · PubMed · Cited by 22
Vashisht, S., & Bagler, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049401 · Cited by 21
“HPN [28] TFF3 [29] BGLAP [30] ERBB3 [31] PSMD9, CDKN1A [27] ERBB2, EGFR [32] PALB, TGFB1, EGFR, BMP [33] BIN1, MYC, ABL1 [34] MAGEA1 [35] MMP1, MMP2, MMP13, DRG1, PTEN, NME1, CD82, KISS1, BRMS1, MAP2K4, TP53 [36]”
Hsu, Y.-H., Wu, C.-Y., Hsing, C., Lai, W.-T., Wu, L., & Chang, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139871 · Cited by 21
Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer
D’Oronzo, S., Silvestris, E., Paradiso, A., Cives, M., & Tucci, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21083022 · Cited by 21
“Furthermore, expression of the receptor activator of nuclear factor k-B (RANK) by tumor cells has been found to contribute to their attraction towards osteolytic areas [21].”
BackgroundHinz, N., Baranowsky, A., Horn, M., Kriegs, M., Sibbertsen, F., Smit, D. J., Clézardin, P., Lange, T., Schinke, T., & Jücker, M. (2021) · Cells · doi:10.3390/cells10020430 · Cited by 21
“CTGF and RANK are part of the vicious cycle in bone metastasis that promotes osteolysis [61,62].”
BackgroundThe Mesenchymal-Like Phenotype of the MDA-MB-231 Cell Line
Boon, K. (2011) · InTech eBooks · doi:10.5772/20666 · Cited by 21
“In addition, a recent study described the role of nuclear factor-kappa B (NF-B) and its ligand in the metastasis of breast cancer cells to the bone matrix (Jones et al., 2006).”
BackgroundQu, Z., An, H., Feng, M., Huang, W., Wang, D., Zhang, Z., & Yan, L. W. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17467 · Cited by 20
Meister, F., Verhoeven, S., Mantas, A., Liu, W., Jiang, D., Heij, L. R., Heise, D., Bruners, P., Lang, S. A., Ulmer, T. F., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-21652-z · Cited by 20
Télétchéa, S., Stresing, V., Hervouet, S., Baud’huin, M., Heymann, M., Bertho, G., Charrier, C., Ando, K., & Heymann, D. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2170 · Cited by 20
“5mg/mL) to activate downstream signaling.((6,45))”
BackgroundChronic stress, sympathetic activation and skeletal metastasis of breast cancer cells
Elefteriou, F. (2015) · BoneKEy Reports · doi:10.1038/bonekey.2015.61 · Cited by 20
“It also stimulates melanoma, breast, prostate and lung cancer cell migration in vitro(40,41) and melanoma cancer cell bone metastasis in vivo.(35) Finally, RANK immunohistochemical positivity in combination with CXCR4 positivity identified breast cancer patients whose disease has a high probability to metastasize to b…”
BackgroundHein, A., Bayer, C., Schrauder, M. G., Häberle, L., Heusinger, K., Strick, R., Ruebner, M., Lux, M. P., Renner, S. P., Schulz‐Wendtland, R., et al. (2014) · BioMed Research International · doi:10.1155/2014/842452 · Cited by 20
“Polymorphisms in the RANK/RANKL Genes and Their Effect on”
BackgroundWang, J., Liu, Y., Wang, L., Sun, X. G., & Wang, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.6795 · Cited by 20
Kodrič, K., Zupan, J., Kranjc, T., Komadina, R., Mlakar, V., Marc, J., & Lovšin, N. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0294-3 · Cited by 20
Wang, K., Wang, J. H., Baskaran, H., Wang, R., & Jurevic, R. (2012) · Head & Neck Oncology · doi:10.1186/1758-3284-4-41 · Cited by 20
“There are many signaling pathways involved in cell migration, including actin and microtubule dynamics, cell-cell and cellextracellular matrix adhesion, and intracellular trafficking of proteins [3].”
BackgroundBone targeted therapy for preventing skeletal-related events in metastatic breast cancer
Irelli, A., Cocciolone, V., Cannita, K., Zugaro, L., Staso, M. D., Baldi, P. L., Paradisi, S., Sidoni, T., Ricevuto, E., & Ficorella, C. (2016) · Bone · doi:10.1016/j.bone.2016.04.006 · Cited by 20
“Hence RANKL has an important role in cell migration and the tissue-specific metastatic behavior of cancer cells [36].”
BackgroundEctodomain Shedding of Receptor Activator of NF-κB Ligand
Hikita, A., & Tanaka, S. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72009-8_2 · Cited by 20
Osteoclasts eat stem cells out of house and home
Purton, L. E., & Scadden, D. T. (2006) · Nature Medicine · doi:10.1038/nm0606-610 · Cited by 20
Martin, T. J., & Mundy, G. R. (2007) · Nature · doi:10.1038/nature05657 · Cited by 20
Mécanismes de formation des métastases osseuses
Peyruchaud, O. (2007) · Journal de la Société de Biologie · doi:10.1051/jbio:2007033 · Cited by 20
“…que le facteur majeur de la résorption osseuse, RANK-L, sécrété par les ostéoblastes est un facteur d’attraction spécifique des cellules de cancer du sein, de la prostate et du mélanome, en interagis-sant avec le récepteur RANK exprimé à la surface des cellules tumorales (Jones et al ., 2006).”
BackgroundMutations within the TNF-Like Core Domain of RANKL Impair Osteoclast Differentiation and Activation
Cheng, T., Pavlos, N. J., Wang, C., Tan, J. W.-Y., Lin, J., Cornish, J., Zheng, M., & Xu, J. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0465 · Cited by 20
Role of RANK and Akt1 activation in human osteosarcoma progression: A clinicopathological study
Zhu, J., Liu, Y., Zhu, Y., Zeng, M., Xie, J., Lei, P., Li, K., & Hu, Y. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4360 · Cited by 19
“In addition, in vitro analyses have indicated that, through the activation of RANK, RANKL modulates gene expression involved in a wide range of cell activities such as protein synthesis and DNA regulation to affect cellular fate (5,15).”
Pilard, C., Roncarati, P., Ancion, M., Luyckx, M., Renard, M., Reynders, C., Lerho, T., Poulain, F., Bruyère, D., Lebeau, A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010753 · Cited by 19
“9 53–55 It is however important to mention that the studies available in the literature have almost exclusively focused their attention on the direct effect of RANKL on epithelial tumor cells while, interestingly, single-cell transcriptomic data highlighted that other cell types (eg, endothelial,…”
Lydon, J. P. (2010) · Nature · doi:10.1038/465695a · Cited by 19
RANK and EGFR in invasive breast carcinoma
Papanastasiou, A. D., Sirinian, C., Plakoula, E., Zolota, V., Zarkadis, I. K., & Kalofonos, H. P. (2017) · Cancer Genetics · doi:10.1016/j.cancergen.2017.07.004 · Cited by 19
TRAF6 maintains mammary stem cells and promotes pregnancy-induced mammary epithelial cell expansion
Yamamoto, M., Abe, C., Wakinaga, S., Sakane, K., Yumiketa, Y., Taguchi, Y., Matsumura, T., Ishikawa, K., Fujimoto, J., Semba, K., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0547-7 · Cited by 19
Optimal cell traction forces in a generalized motor-clutch model
Alonso‐Matilla, R., Provenzano, P. P., & Odde, D. J. (2023) · Biophysical Journal · doi:10.1016/j.bpj.2023.07.012 · Cited by 19
“…complications, tissue remodeling and immune modulation in inflam-matory responses near implanted medical devices (78,79), bone cancer metastasis (80), fibrosis in cancer (81,82), calcified bone remodeling processes and homeostasis (83), and dental lamina development and degradation processes (84).”
Zhou, X., & Liu, J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-618 · Cited by 19
“In fact, some immune related genes are essential in bone metastasis of breast cancer [42-44], and their family members, such as FAS, IL2RG and IL7R, have shown dysregulated in our work and have been reported to be either metastasis related or bone metastasis related [31,35,45].”
BackgroundBoopalan, T., Arumugam, A., Parada, J., Saltzstein, E. C., & Lakshmanaswamy, R. (2014) · Cancer Science · doi:10.1111/cas.12571 · Cited by 19
Dombkowski, A. A., Sultana, Z., Craig, D. B., & Jamil, H. M. (2011) · Cancer Informatics · doi:10.4137/cin.s6631 · Cited by 19
Yan, X., Wang, Z., Qi, P.-F., Li, G., & Zhu, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.056 · Cited by 19
The role of the RANKL/RANK/OPG system in the central nervous systems (CNS)
Hanada, R. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01143-9 · Cited by 18
Functional Genomic Analysis of Breast Cancer Metastasis: Implications for Diagnosis and Therapy
Yu, Z., Song, M. L., Chouchane, L., & Ma, X. (2021) · Cancers · doi:10.3390/cancers13133276 · Cited by 18
Mechanisms of Ovarian Cancer-Associated Cachexia
Callaway, C. S., Mouchantat, L. M., Bitler, B. G., & Bonetto, A. (2023) · Endocrinology · doi:10.1210/endocr/bqad176 · Cited by 18
Yin, X., Zhu, X., & Wang, Z. (2021) · Advanced Materials Interfaces · doi:10.1002/admi.202100494 · Cited by 18
Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma
Fotia, G., Stellato, M., Guadalupi, V., Sepe, P., Claps, M., Giannatempo, P., Bottiglieri, A., Rametta, A., Taglialatela, I., Vela, C., et al. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01395-4 · Cited by 18
The human microbiota key role in the bone metabolism activity.
Inchingolo, A. M., Isacco, C. G., Inchingolo, A. D., Nguyen, K. C. D., Cantore, S., Santacroce, L., Scacco, S., Cirulli, N., Corriero, A., Puntillo, F., et al. (2023) · PubMed · doi:10.26355/eurrev_202303_31803 · Cited by 18
“…progressive decay linked to lower production of osteoid matrix, elastin, and collagens accompanied by a lower mineralization process in both cancellous and cortical bone substrates with an accelerated trend towards the remodeling mechanism due to an abnormal higher osteoclastic activity 67-72 .”
BackgroundShang, W.-Q., Li, H., LIU, L.-B., Chang, K., YU, J.-J., Xie, F., Li, M., & Yu, J. (2015) · Oncology Reports · doi:10.3892/or.2015.4303 · Cited by 18
Meng, Y.-H., Li, H., Chen, X., Liu, L.-B., Shao, J., Chang, K.-K., Du, M., Jin, L.-P., Li, M., & Li, D.-J. (2013) · Placenta · doi:10.1016/j.placenta.2013.04.020 · Cited by 18
“bone remodeling [15e18], lymph node formation [19,20], establishment of the thymic microenvironment [21], mammary gland development during pregnancy [22e24], and bone metastasis of cancer [25].”
BackgroundChen, X., Liu, W., Wang, Y.-X., Chen, W., Li, H., Chen, Y., Du, X., Peng, F., Zhou, W., Xu, Z., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.03.013 · Cited by 18
Clinical Impact of RANK Signalling in Ovarian Cancer
Wieser, V. E., Sprung, S., Tsibulak, I., Haybaeck, J., Hackl, H., Fiegl, H., Marth, C., & Zeimet, A. G. (2019) · Cancers · doi:10.3390/cancers11060791 · Cited by 18
“Moreover, the RANK/RANKL/OPG system also plays essential roles in immunity and tumourigenesis [5,6] and RANK/RANKL cancer cell expression correlated with metastasis and tumour progression in human breast cancer (BC) [7].”
BackgroundBasic and clinical associations between bone and cancer
He, F., & Matsumoto, Y. (2020) · Immunological Medicine · doi:10.1080/25785826.2020.1754084 · Cited by 18
Lovšin, N., & Marc, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031054 · Cited by 18
Schubert, A., Schulz, H., Emons, G., & Gründker, C. (2008) · Gynecological Endocrinology · doi:10.1080/09513590802095845 · Cited by 18
“Besides its function in bone resorption, RANKL plays an important role in migration of breast cancer cells and bone metastasis [19].”
BackgroundBoyce, B. F., Zuscik, M. J., & Xing, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804182-6.00011-3 · Cited by 18
Adipocyte–Tumor Interactions in the Bone Marrow Niche: Implications for Metastasis and Therapy
Dabaliz, A., Hakawati, M. N. A., Alrashdan, N., Alrashdan, S., Bakir, M. A., & Mohammad, K. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199781 · Cited by 17
Yamada, T., Tsuda, M., Wagatsuma, T., Fujioka, Y., Fujioka, Y., Satoh, A. O., Horiuchi, K., Nishide, S., Nanbo, A., Totsuka, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep23545 · Cited by 17
Zhang, Z., Miao, L., Sun, W., Jiao, B., Wang, B., Li, Y., & Huang, C. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00368 · Cited by 17
Zhou, X., Liu, J., Ye, X., Wang, W., & Xiong, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-s12-s6 · Cited by 17
Hypoxia response pathway in border cell migration
Djagaeva, I., & Doronkin, S. (2010) · Cell Adhesion & Migration · doi:10.4161/cam.4.3.11790 · Cited by 17
Cui, N., Nomura, T., Takano, N., Wang, E., Zhang, W., Onda, T., & Shibahara, T. (2010) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2010.128 · Cited by 17
Spizzo, G., Seeber, A., & Mitterer, M. (2009) · PubMed · Cited by 17
Targeted therapy in prostate cancer
Corcoran, N. M., & Gleave, M. E. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.04030.x · Cited by 16
“It has been demonstrated in vitro that coculture of prostate cancer cells with osteoclasts increases RANKL expression and decreases OPG production, and, in animal models, inhibition of RANKL decreases the development and progression of bone metastases.(64,65) Denosumab is a humanized monoclonal IgG2 antibody that bind…”
BackgroundInference of Tumor Phylogenies from Genomic Assays on Heterogeneous Samples
Subramanian, A., Shackney, S. E., & Schwartz, R. S. (2012) · BioMed Research International · doi:10.1155/2012/797812 · Cited by 16
RANKL and RANK in Cancer Therapy
Onji, M., & Penninger, J. M. (2022) · Physiology · doi:10.1152/physiol.00020.2022 · Cited by 16
Self-citationThe Role of Bone Microenvironment, Vitamin D and Calcium
Santini, D., Pantano, F., Vincenzi, B., Tonini, G., & Bertoldo, F. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-21892-7_2 · Cited by 16
“Finally, based on high constitutive RANK expression in breast cancer cell lines, recent data actually indicate that RANK expression by cancer cells determines whether tumors predominantly migrate into bone, where the corresponding ligand RANKL is abundantly expressed (Jones et al. 2006).”
BackgroundGentile, M., Centonza, A., Lovero, D., Palmirotta, R., Porta, C., Silvestris, F., & D’Oronzo, S. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100337 · Cited by 16
“In addition, the expression of calcium sensing receptor and the receptor activator of nuclear factor r-B (RANK) have been shown to participate in BC cell attraction towards osteolytic areas [27,28].”
BackgroundDenosumab: a new option in the treatment of bone metastases from urological cancers
Yuasa, T., Yamamoto, Urakami, Fukui, & Yonese (2012) · OncoTargets and Therapy · doi:10.2147/ott.s30578 · Cited by 16
“Besides indirect activity via prevention of osteoclast function, denosumab was demonstrated to act directly on RANK-expressing cancer cells, including breast, prostate and melanoma cells.(62) Jones et al demonstrated that RANKL plays an important role in the cell migration and tissue-specific metastatic behavior of ca…”
BackgroundInfluentialZhou, W., Xie, P., Pang, M., Yang, B., Fang, Y., SHU, T., Liu, C., Wang, X., Zhang, L., Li, S., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2705 · Cited by 16
Immunization With RANKL Inhibits Osteolytic Bone Metastasis in Breast Cancer
Kim, B., Cho, Y. J., Park, M., & Lim, W. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000393 · Cited by 15
Progesterone Receptor Signaling in the Breast Tumor Microenvironment
Boonyaratanakornkit, V., McGowan, E. M., Márquez‐Garbán, D. C., Burton, L., Hamilton, N. M., Pateetin, P., & Pietras, R. J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73119-9_21 · Cited by 15
Brouns, A., Hendriks, L. E. L., den Berge, I. J. R.-V., Driessen, J. H. M., Roemen, G. M. J. M., van Herpen, B. L. J., Dekkers, Z., Heitzer, B., Leunissen, D. J. G., Moonen, L., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1145001 · Cited by 15
“EGFR+ KRAS+ EGFR/KRAS wildtype 23 (32) 36 (49) 14 (19)”
Yamashita, S., Katsumi, H., Shimizu, E., Nakao, Y., Yoshioka, A., Fukui, M., Kimura, H., Sakane, T., & Yamamoto, A. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.10.001 · Cited by 15
Karatolios, K., Pankuweit, S., Goettsch, C., Hofbauer, L. C., Timmesfeld, N., Al‐Fakhri, N., Maisch, B., & Schoppet, M. (2011) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2011.12.003 · Cited by 15
Molecular treatment strategies and surgical reconstruction for metastatic bone diseases
Zou, X., Zou, L., He, Y., & Bünger, C. E. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.012 · Cited by 15
“Functional RANK expression on cancer cells has been reported.(46,47) Therefore, a new insight in bone metastasis process of the prostate cancer has been proposed.”
BackgroundBenedikt, M., Mahlum, E., Shogren, K. L., Subramaniam, M., Spelsberg, T. C., Yaszemski, M. J., & Maran, A. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22473 · Cited by 15
“OPG has been shown to regulate the RANKL-induced epithelial cancer cell migration and bone metastasis [Jones et al., 2006].”
BackgroundGene Translocations in Musculoskeletal Neoplasms
Krishnan, B., Khanna, G., & Clohisy, D. R. (2008) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-008-0342-0 · Cited by 15
“Phase III trials are also underway for inhibitors of RANKL as alternatives to bisphosphonates in treating patients with osteosarcoma [48].”
Can We Predict Who's at Risk for Developing Bone Metastases in Breast Cancer?
Korde, L. A., & Gralow, J. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.7038 · Cited by 15
Cancer Pain Is Not One-Size-Fits-All: Evolving from Tradition to Precision
Shapoo, N., Rehman, A., Rojas, C. A. I., Gotlieb, V. K., & Boma, N. (2025) · Clinics and Practice · doi:10.3390/clinpract15100173 · Cited by 14
“Tumor cells, stromal cells, and activated immune cells secrete several mediators, including endothelin, nerve growth factors, protons, and pro-inflammatory cytokines such as tumor necrosis factor TNF-α , IL-6, IL-1 β , and prostaglandin E2, which activate nociceptors [21].”
Immune Regulation of the Metastatic Process
Pulido, Á. D. M., & Ruffell, B. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.004 · Cited by 14
“However, these findings may be model and/or organ dependent, and RANKL can directly promote mouse and human epithelial cell migration and bone metastasis (Jones et al. 2006).”
BackgroundPrognostic significance of preoperative osteopenia on outcomes after gastrectomy for gastric cancer
Fukushima, N., Tsuboi, K., Nyumura, Y., Hoshino, M., Masuda, T., Suzuki, T., Kajimoto, T., Yano, F., & Eto, K. (2022) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12635 · Cited by 14
Gomes, I., Gallego-Paez, L. M., Jiménez, M., Santamaría, P. G., Mansinho, A., Sousa, R., Abreu, C., González‐Suárez, E., Costa, L., & Casimiro, S. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101120 · Cited by 14
The 100 most cited papers on bone metastasis: A bibliometric analysis
Li, H., Wu, H., Abakumov, M. A., Xu, Y., Lin, Y., Chekhonin, V. P., Peltzer, K., Abbas, K. S., Li, S., & Zhang, C. (2022) · Journal of bone oncology · doi:10.1016/j.jbo.2022.100443 · Cited by 14
Antineoplastic activity of zoledronic acid and denosumab.
Zwolak, P., & Dudek, A. Z. (2013) · PubMed · Cited by 14
Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?
von Moos, R., & Haynes, I. (2013) · Journal of Clinical Medicine · doi:10.3390/jcm2030089 · Cited by 14
“RANKL in both the transgenic mice overexpressing RANK and the wild-type mice, and triggered epithelial cell proliferation [29,31].”
BackgroundInfluentialSakuma, T., Nakamoto, T., Hemmi, H., Kitazawa, S., Kitazawa, R., Notomi, T., Hayata, T., Ezura, Y., Amagasa, T., & Noda, M. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24066 · Cited by 14
“These events are dependent on complexity of cell and tissue interactions including linkage between membrane molecule and Src (Liu et al., 2011), tumor cell migratory activity and the microenvironmental factors (Jones et al., 2006).”
BackgroundOsteoprotegerin, Rank ve Rank Ligandi
Kurban, S., & Mehmetoğlu, İ. (2007) · Turkish Journal of Biochemistry · Cited by 14
Najar, M., Fayyad‐Kazan, H., Faour, W. H., Badran, B. M., Journé, F., & Lagneaux, L. (2016) · Inflammation Research · doi:10.1007/s00011-016-1000-8 · Cited by 14
“Moreover, previous studies showed that cancer cells expressing RANK preferentially migrate to tissues expressing significant levels of RANKL [14, 15].”
BackgroundRANKL triggers resistance to TRAIL‐induced cell death in oral squamous cell carcinoma
Ethiraj, P., Sambandam, Y., Hathaway‐Schrader, J. D., Haque, A., Novince, C. M., & Reddy, S. V. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29086 · Cited by 14
“In addition to functioning as a critical osteoclastogenic cytokine, RANKL plays an important role in cancer cell migration (Jones et al., 2006).”
BackgroundHGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway
Yao, Y., Fang, Z.-M., Chen, H., Li, Y., Min, D.-L., Tang, L.-N., Yu, W.-X., Kung, H. F., Lin, M. C.-M., & Shen, Z. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.38 · Cited by 14
Role of denosumab in prostate cancer
Helo, S., Manger, J. P., & Krupski, T. L. (2012) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2012.2 · Cited by 14
Hu, H., Li, X., Xu, Z., Tao, Y., Zhao, L., You, H., Xu, G., Zhang, T., Zhang, Y., Fan, H., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105503 · Cited by 13
Ardura, J. A., Gutiérrez-Rojas, I., Álvarez‐Carrión, L., Rodríguez-Ramos, M. R., Pozuelo, J. M., & Alonso, V. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz105 · Cited by 13
Lou, J., Gong, B., Li, Y., Guo, Y., Li, L., Wang, J., Liu, W., You, Z., Zhang, H., Pan, F., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1332303 · Cited by 13
Targeted Treatments of Bone Metastases in Patients with Lung Cancer
Hirsh, V. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00146 · Cited by 13
“RANKL inhibition may have a direct antineoplastic effect on lung cancer cells via apoptosis or anti-migration activity (63).”
BackgroundZhang, X., Song, Y., Song, N., Zhang, L., Wang, Y., Li, D., Wang, Z., Qu, X., & Liu, Y. (2018) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20176265 · Cited by 13
Lai, H. W., Takahashi, K., Nakajima, M., Tanaka, T., & Ogura, S. (2021) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2021.112191 · Cited by 13
Inhibition of gap junction channel attenuates the migration of breast cancer cells
Zhao, K., Wang, W., Guan, C., Cai, J., & Wang, P. (2011) · Molecular Biology Reports · doi:10.1007/s11033-011-1013-x · Cited by 13
“Moreover, marked RANK expression was detected in a large number of primary human breast tumour samples as well as in metastatic cancer cells in local lymph nodes [4].”
Background
Metadata
- Authors
- Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., Morony, S., Rubin, E., Sarao, R., Hojilla, C. V., Komnenovic, V., Kong, Y.-Y., Schreiber, M., Dixon, S. J., Sims, S. M., Khokha, R., Wada, T., & Penninger, J. M.
- Affiliations
- Institute of Molecular Biotechnology (AT)
- University Health Network (CA)
- McGill University (CA)
- Amgen (United States) (US)
- University of Toronto (CA)
- Pohang University of Science and Technology (KR)
- Medical University of Vienna (AT)
- Western University (CA)
- Corresponding author
- Penninger, Josef M.
- ORCID
- Venue
- Nature
- Published
- 2006-03
- Volume
- 440
- Issue
- 7084
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051255001
- Cited by
- 796
- References
- 22
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 24 · 2023: 32 · 2022: 33 · 2021: 43 · 2020: 43 · 2019: 39 · 2018: 28 · 2017: 43 · 2016: 36 · 2015: 42 · 2014: 45 · 2013: 47 · 2012: 68
- FWCI
- 18.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- European Commission
- Oesterreichische Nationalbank
- Canadian Institutes of Health Research
- National Cancer Institute
- Institute of Musculoskeletal Health and Arthritis
- Canadian Arthritis Network
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- RANKL, RANK, bone metastasis, tumor cell migration, osteoprotegerin, melanoma, breast cancer, tumor microenvironment, NF-κB signaling
- MeSH terms
- Animals, Bone Neoplasms, Breast Neoplasms, Carrier Proteins, Cell Differentiation, Cell Movement, Epithelial Cells, Female, Humans, Melanoma, Membrane Glycoproteins, Neoplasm Metastasis, Organ Specificity, Paralysis, Signal Transduction, Cell Death, Cell Line, Tumor, Cell Proliferation, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.